Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Atlantic International Corp.

$0.9

-0.02 (-2.16%)

C 41Pipeline Score NOT_PHARMA · Commercial
Market Cap
115.86 M
EPS
-1.08
P/E Ratio
-1.35 $
Value Trade
587.97 K
SEC Financials
Q1 2026

  • Dilution Risk

    70%

  • Revenue

    249.89 M

  • Operating CF

    -9.89 M

  • Total Assets

    981.05 M

  • Total Liabilities

    926.31 M

  • Equity

    42.43 M

  • D/E Ratio

    12,345

-5.96 %
Week
-29.7 %
1 Month
-46.62 %
3 Month
-40.34 %
6 Month
-99.97 %
5 Year
-99.97 %
All Time
Cash Data
Caution

  • Cash Position

    24.10 M

  • Monthly Burn

    3.30 M

  • Runway

    6.4 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    Jun 22, 2026
Overview
Volume
18.83 M
52 Week Range
1.16 - 5.25
% held by Insiders
66 %
% held by Institutions
3.55 %
Enterprise Value
203.45 M
Total Shares
76.33 M
Short %
2.7 %
Float Shares
23.28 M
Company Description
Founded:2014
https://www.atlantic-internati...

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Unlock the full Catalyst Timeline
Past FDA Catalysts & PDUFA Decisions
Date Drug Catalyst Stage Outcome Reaction Event Move % Best Trade %
—
Example Drug
Phase 3 data readout
Phase 3
—
–
0%
0%
—
Example Drug
Phase 3 data readout
Phase 3
—
–
0%
0%
—
Example Drug
Phase 3 data readout
Phase 3
—
–
0%
0%
Unlock Historical Catalyst data
Drug Pipeline Intelligence
C41
Pipeline Score
$173M
Pipeline Value
Valuation Signal
12
Drugs Scored
1.5x
rNPV / MCap
Top 61%
Micro Cap
(rank 357 of 913)
Percentile Rank
Atlantic International Corp. carries a moderate pipeline score (41/100), with $1.9B risk-adjusted pipeline value, led by Immune Globulin in Primary Immunodeficiency (Phase 3), across $59B in total addressable markets.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Immune Globulin
Monoclonal antibody		Primary ImmunodeficiencyPhase 3NCT0226916374% $478M COMPLETED 82 - -Jan 11, 2019 -Nov 5, 2021
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01

The study met its primary endpoint demonstrating statistically significant improvement.

Read More

Phase 3 Study Results Announcement

Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01

The study met its primary endpoint demonstrating statistically significant improvement.

Read More

Phase 3 Study Results Announcement

Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01

The study met its primary endpoint demonstrating statistically significant improvement.

Read More

Phase 3 Study Results Announcement

Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in ATLN
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
ATLN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How ATLN ranks across every disease it competes in
Competitive Position is a premium feature
See how ATLN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial